BidaskClub lowered shares of Radius Health (NASDAQ:RDUS) from a sell rating to a strong sell rating in a research note published on Thursday morning.
Other research analysts have also issued research reports about the stock. Maxim Group restated a positive rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. Zacks Investment Research lowered shares of Radius Health from a hold rating to a sell rating in a research report on Wednesday, October 4th. Goldman Sachs Group restated a neutral rating and issued a $45.00 price target on shares of Radius Health in a research report on Friday, October 6th. Jefferies Group restated a hold rating and issued a $38.00 price target (up previously from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th. Finally, Cantor Fitzgerald restated a buy rating and issued a $58.00 price target on shares of Radius Health in a research report on Friday, November 3rd. Three analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $48.00.
Radius Health (NASDAQ:RDUS) traded up $4.19 during midday trading on Thursday, hitting $31.60. 3,177,600 shares of the company were exchanged, compared to its average volume of 974,338. Radius Health has a fifty-two week low of $24.66 and a fifty-two week high of $49.39. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53.
In other news, major shareholder Growth N. V. Biotech acquired 50,000 shares of the stock in a transaction on Tuesday, November 14th. The shares were purchased at an average cost of $26.25 per share, for a total transaction of $1,312,500.00. Following the transaction, the insider now owns 5,698,799 shares in the company, valued at approximately $149,593,473.75. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 150,000 shares of the stock in a transaction on Thursday, September 14th. The shares were purchased at an average price of $33.45 per share, for a total transaction of $5,017,500.00. Following the completion of the transaction, the insider now owns 5,448,799 shares in the company, valued at approximately $182,262,326.55. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 367,678 shares of company stock worth $11,746,498. 15.00% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of RDUS. Teachers Advisors LLC grew its position in Radius Health by 4.4% during the 1st quarter. Teachers Advisors LLC now owns 54,024 shares of the biopharmaceutical company’s stock worth $2,088,000 after purchasing an additional 2,289 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Radius Health by 144.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 12,562 shares of the biopharmaceutical company’s stock valued at $568,000 after buying an additional 7,417 shares during the period. Sei Investments Co. boosted its stake in shares of Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 690 shares during the period. TD Asset Management Inc. boosted its stake in shares of Radius Health by 68.0% during the 2nd quarter. TD Asset Management Inc. now owns 145,970 shares of the biopharmaceutical company’s stock valued at $6,602,000 after buying an additional 59,100 shares during the period. Finally, Pictet Asset Management Ltd. boosted its stake in shares of Radius Health by 20.0% during the 2nd quarter. Pictet Asset Management Ltd. now owns 641,388 shares of the biopharmaceutical company’s stock valued at $22,205,000 after buying an additional 106,849 shares during the period.
ILLEGAL ACTIVITY NOTICE: “Radius Health (RDUS) Downgraded to Strong Sell at BidaskClub” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/12/11/radius-health-rdus-downgraded-to-strong-sell-at-bidaskclub.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.